Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor dysfunction, cognitive decline, and significant impairment in daily life. Despite advancements in symptomatic treatment, no available therapies can halt or reverse disease progression.  JY-UEX001 is our UC-MSC-derived exosome therapy being developed for the treatment of Parkinson’s disease. By harnessing the neuroprotective and anti-inflammatory properties of exosomes, this therapy aims to reduce neuroinflammation, enhance neuronal survival, and promote neuroregeneration. The cell-free nature of exosomes may provide an advantage in terms of safety, scalability, and ease of administration compared to traditional cell-based therapies.  Preclinical studies have demonstrated the potential of UC-MSC-derived exosomes in improving neurodegeneration-associated pathologies. We are advancing JY-UEX001 towards clinical development, with a focus on establishing safety, optimal dosing, and therapeutic efficacy for Parkinson’s disease patients.